SAN DIEGO, Nov. 30, 2016 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that four
abstracts will be presented at the 2016 Advances in Inflammatory
Bowel Diseases: Crohn's & Colitis Foundation's Clinical and
Research Conference on Friday, December
9 at 6:00pm ET. The
conference is taking place December
8-10 at the Walt Disney World Dolphin Hotel in Orlando, Florida. The data will also be
published in the February issue of the Inflammatory Bowel
Diseases Journal, a peer-reviewed medical journal bringing the
most current information in clinical and basic sciences to
physicians caring for patients with inflammatory bowel diseases
(IBD), and investigators performing research in IBD and related
fields.
The following abstracts will be presented:
Title: Preclinical Safety Assessment of Etrasimod
(APD334), an Oral Sphingosine-1-Phosphate Receptor (S1P) Modulator
with a Unique Profile
Session Type: Poster Presentation
Poster Board Number: P-250
Date: Friday, December 9 at
6:00pm-7:00pm ET
Location: Exhibit Hall - Atlantic B-C
Title: The Sphingosine-1-Phosphate Receptor (S1P)
Modulator Etrasimod (APD334) Demonstrates Limited Effects on Heart
Rate in Preclinical Testing
Session Type: Poster
Presentation
Poster Board Number: P-261
Date: Friday, December 9 at
6:00pm-7:00pm ET
Location: Exhibit Hall - Atlantic B-C
Title: Safety, Pharmacokinetics and Pharmacodynamics of
Etrasimod (APD334), an Oral Selective S1P Receptor Modulator, after
Single Dose Escalation, in Healthy Volunteers
Session Type:
Poster Presentation
Poster Board Number: P-179
Date: Friday, December 9 at
6:00pm-7:00pm ET
Location: Exhibit Hall - Atlantic B-C
Title: Etrasimod (APD334), a Potent, Selective, Oral S1P
Receptor Modulator With Autoimmune Disease-Modifying Activity that
Exhibits Favorable PK/PD Properties in Healthy
Volunteers
Session Type: Poster Presentation
Poster Board Number: P-180
Date: Friday, December 9 at
6:00pm-7:00pm ET
Location: Exhibit Hall - Atlantic B-C
About Arena Pharmaceuticals
We are a biopharmaceutical
company focused on developing novel, small molecule drugs across a
range of therapeutic areas. We have three primary proprietary
investigational clinical programs: etrasimod (APD334) in Phase 2
evaluation for ulcerative colitis, APD371 entering Phase 2
evaluation for the treatment of pain associated with Crohn's
disease, and ralinepag (APD811) in Phase 2 evaluation for pulmonary
arterial hypertension (PAH). Additionally, we have
collaborations with the following pharmaceutical companies: Eisai
Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences Ltd.
(Phase 2 candidate), and Boehringer Ingelheim International GmbH
(preclinical candidate).
Our US operations are located in San
Diego, California. Our primary clinical operations are
located in Zug, Switzerland, and
our commercial manufacturing for BELVIQ is located in Zofingen,
Switzerland.
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about the upcoming presentation; the publication of the
data; and Arena's focus, primary programs and collaborations. For
such statements, Arena claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Arena's expectations. Factors that could
cause actual results to differ materially from the forward-looking
statements include those disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking
statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Contact: Arena Pharmaceuticals,
Inc.
Kevin R. Lind, Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Logo - http://photos.prnewswire.com/prnh/20161107/436843LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-four-upcoming-presentations-at-the-2016-advances-in-inflammatory-bowel-diseases-crohns--colitis-foundations-clinical-and-research-conference-300370082.html
SOURCE Arena Pharmaceuticals, Inc.